Table 2 In vitro sensitivity to the Aurora kinases-targeting drugs VX-680 and ZM447439 of a panel of 10 human osteosarcoma cell lines

From: Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

 

VX-680

ZM447439

Cell line a

Mean IC50 value ( μ M)b

s.d.

Mean IC50 value ( μ M)

s.d.

U-2OS

0.4

0.2

2.7

0.1

Saos-2

0.4

0.2

2.7

0.3

IOR/OS18

2.2

0.5

5.5

1.2

IOR/OS9

0.2

0.2

0.7

0.2

U-2OS/DX580

52.8

6.5

11.2

2.3

Saos-2/DX580

16.3

2.5

13.8

2.3

U-2OS/MTX300

0.6

0.1

4.3

0.4

Saos-2/MTX300

0.3

0.2

0.6

0.2

U-2OS/CDDP4  μ g

15.2

1.2

4.4

1.0

Saos-2/CDDP6  μ g

8.4

2.6

2.7

0.8

  1. aThe cell line panel included four drug-sensitive human osteosarcoma cell lines (U-2OS, Saos-2, IOR/OS18, IOR/OS9) and U-2OS or Saos-2 variants resistant to doxorubicin (U-2OS/DX580, Saos-2/DX580), methotrexate (U-2OS/MTX300, Saos-2/MTX300), or cisplatin (U-2OS/CDDP4 μg, Saos-2/CDDP6 μg).
  2. bIC50 values were calculated after 96 h of drug treatment. Data refer to the mean IC50±s.d. of three different experiments.
Back to article page